A Randomized, Phase 2 Study of the Efficacy and Tolerability of Veliparib in Combination With Temozolomide or Veliparib in Combination With Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Subjects With BRCA1 or BRCA2 Mutation and Metastatic Breast Cancer
A Randomized, Phase 2 Study of the Efficacy and Tolerability of Veliparib in Combination With Temozolomide or Veliparib in Combination With Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Subjects With BRCA1 or BRCA2 Mutation and Metastatic Breast Cancer
The primary objective of the study is to assess the progression-free survival (PFS) of oral veliparib in combination with TMZ or in combination with carboplatin and paclitaxel compared to placebo plus carboplatin and paclitaxel in subjects with BRCA1 or BRCA2 mutation and locally recurrent or metastatic breast cancer.
Inclusion Criteria:
Exclusion Criteria:
West Hollywood, California 90048, United States
Chicago, Illinois 60611-2927, United States
New York, New York 10065-6007, United States
Hershey, Pennsylvania 17033, United States
Berazategui, Buenos Aires, 1884, Argentina
Lajeado, Rio Grande do Sul 95900-000, Brazil
Petakh Tikva, Tel Aviv 4941492, Israel
Rzeszów, Podkarpackie Voivodeship 35-021, Poland
Moscow, Moscow 115478, Russia
Murmansk, 183047, Russia
Dnipro, 49102, Ukraine
Poltava, 36011, Ukraine